Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 9/20 | 0.37 |
| ▸ | ACACA | Q13085 | 8/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3498469 | 0.99 | ACACB (0.36) | ACACBACACAHRH3CHRM2CHRM3 | |
| SCHEMBL13312062 | 0.86 | ACACB (0.49) | ACACBACACACHRM2CHRM3L3MBTL3 | |
| Hydrochloric Acid SCHEMBL3498452 | 0.85 | ACACB (0.48) | ACACBACACACHRM2CHRM3 | |
| SCHEMBL13312077 | 0.85 | ACACB (0.34) | ACACBACACAHRH3 | |
| SCHEMBL3495995 | 0.85 | ACACB (0.44) | ACACBACACAHRH3 | |
| SCHEMBL13312080 | 0.84 | HRH3 (0.36) | ACACBACACAHRH3L3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL3496101 | 0.84 | ACACB (0.44) | ACACBACACAHRH3 | |
| Hydrochloric Acid SCHEMBL3497909 | 0.84 | ACACB (0.34) | ACACBACACAHRH3 | |
| Hydrochloric Acid SCHEMBL3498939 | 0.83 | HRH3 (0.35) | ACACBACACAHRH3 | |
| SCHEMBL13312090 | 0.83 | HRH3 (0.33) | ACACBACACAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | ACACA, CPT1B, PC | ACACB 6/4885ACACA 1/4885HRH3 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.